These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 792350)

  • 21. Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences.
    Medicus RG; Esser AF; Fernandez HN; Müller-Eberhard HJ
    J Immunol; 1980 Feb; 124(2):602-6. PubMed ID: 6766162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 23. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The fractionation of human plasma proteins. I. Affinity purification of human complement properdin.
    DiScipio RG
    Protein Expr Purif; 1994 Apr; 5(2):164-9. PubMed ID: 8054850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Properties of highly purified human properdin.
    Ensky J; Hinz CF; Todd EW; Wedgwood RJ; Boyer JT; Lepow IH
    J Immunol; 1968 Jan; 100(1):142-58. PubMed ID: 4169693
    [No Abstract]   [Full Text] [Related]  

  • 26. An alternative mechanism for the properdin system.
    NELSON RA
    J Exp Med; 1958 Oct; 108(4):515-35. PubMed ID: 13575682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative studies on the properdin-complement system.
    LEON MA
    J Exp Med; 1956 Mar; 103(3):285-93. PubMed ID: 13295486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The properdin system and immunity. XV. Some biologic effects of the administration of zvmosan and other polvsaccharides to rabbits, and the presence of antibodies to zymosan in human and rabbit serum.
    HINZ CF; WEDGWOOD RJ; PILLEMER L
    J Lab Clin Med; 1961 Feb; 57():185-98. PubMed ID: 13714488
    [No Abstract]   [Full Text] [Related]  

  • 29. Activation of the alternative (properdin) pathway by divalent cations.
    Lew FT; Yukiyama Y; Waks HS; Osler AG
    J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purification and functional analysis of human properdin.
    O'Flynn J; Krol MC; Daha MR; van Kooten C
    Methods Mol Biol; 2014; 1100():161-7. PubMed ID: 24218258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.
    Vogt W; Dieminger L; Lynen R; Schmidt G
    Hoppe Seylers Z Physiol Chem; 1974 Feb; 355(2):171-83. PubMed ID: 4215726
    [No Abstract]   [Full Text] [Related]  

  • 32. Isolation of thyroxine-binding globulin (TBG) by immunoadsorption chromatography: some physical and immunochemical characteristics of TBG.
    Kennedy JF; Barnes JA; Matthews JB
    Clin Chim Acta; 1983 Apr; 129(3):251-61. PubMed ID: 6406104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaphylatoxin formation by contact activation of plasma. II. Implication of properdin and an unknown plasma factor in activation by zymosan.
    Brade V; Vogt W
    Eur J Immunol; 1971 Aug; 1(4):295-300. PubMed ID: 4945686
    [No Abstract]   [Full Text] [Related]  

  • 34. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
    J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract]   [Full Text] [Related]  

  • 35. Properdin factor D. II. Activation to D by properdin.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1974 Aug; 140(2):426-36. PubMed ID: 4211020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ULTRACENTRIFUGE STUDIES ON PROPERDIN SERA OF ZYMOSAN-VACCINATED CATTLE, RABBITS, GUINEA PIGS, RATS AND MICE AND ON BOVINE PROPERDIN SERUM FRACTIONS].
    ZIMMERMANN G; KRUEGER K
    Acta Biol Med Ger; 1963; 11():902-17. PubMed ID: 14121884
    [No Abstract]   [Full Text] [Related]  

  • 38. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.
    WARD PA; COCHRANE CG; MUELLER-EBERHARD HJ
    J Exp Med; 1965 Aug; 122(2):327-46. PubMed ID: 14316948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A Streptococci. II. Human plasma cofactor (s) enhancing opsonization of encapsulated organisms.
    STOLLERMAN GH; RYTEL M; ORTIZ J
    J Exp Med; 1963 Jan; 117(1):1-17. PubMed ID: 13984363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of properdin in murine zymosan-induced arthritis.
    Dimitrova P; Ivanovska N; Schwaeble W; Gyurkovska V; Stover C
    Mol Immunol; 2010 Apr; 47(7-8):1458-66. PubMed ID: 20226532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.